ALK Gene - DOAJ

Gain of ALK gene copy number may predict lack of benefit from anti-EGFR treatment in patients with advanced colorectal cancer and RAS-RAF-PI3KCA wild-type status.

According to ALK gene status, the success of 68 patients with advanced colorectal cancer and RAS, BRAF, and PI3KCA are among a growing number of molecularly enriched populations. Although cetuximab and panitumumumab improve patient survival in patients with KRAS-NRAS-BRAF and PI3KCA wild-type metastatic colorectal cancer patients with elevated risk is observed in a small subset of molecularly lipid lipide lipid coding status identifier 68 patients with advanced colorectal cancer and ab and graft cytographically PI3KCA patients with increased gligliab enriched populations, according to metabolically ab enchi In 25 tumors, the ALK gene copy number change was detected. Patients with disomic ALK were significantly higher than those with increase in gene copy number compared to those with reduced gene copy number.

Source link: https://doi.org/10.1371/journal.pone.0092147

Clinical and computed tomography characteristics of non‐small cell lung cancer with ALK gene rearrangement: Comparison with EGFR mutation and ALK/EGFR‐negative lung cancer

The purpose of this review was to analyze the medical and computed tomography results of non-small cell lung cancer patients with the ability to distinguish between ALK gene rearrangement, EGFR mutation, and non-ALK/EGFR. Methods We accepted 201 patients with primary NSCLC who had undergone molecular testing for both ALK gene rearrangement and EGFR mutation. Emphysema with ALK gene rearrangement in NSCLC patients with ALK gene rearrangement was significantly less prevalent than non-ALK/EGFR. Conclusions NSCLC with ALK gene rearrangement was more likely to develop in younger women with a light or no smoking history.

Source link: https://doi.org/10.1111/1759-7714.13017

Identification of ALK gene alterations in urothelial carcinoma.

paraphrasedoutput:BACKGROUND: Anaplastic lymphoma kinase genomic alterations have emerged as a reliable predictor of cancer relief from ALK inhibitor therapy in several cancers. Currently, there is no evidence regarding ALK gene mutations in urothelial carcinoma and its connection with clinical or pathologic characteristics and outcome. METHODS: Samples from patients with advanced UC and correlative clinical records were collected. In the FISH positive case, next generation sequencing was performed using Illumina Genome Analyzer IIx and Illumina HiSeq 2000. In 17 patients, Arm level copy number changes at chromosome 2 were reported. aCGH reported that small copy number changes in the vicinity of ALK locus in 3 patients. The ability of testing ALK inhibitors in UC is worthy of further investigation, but it could be limited to the identification of an enriched population.

Source link: https://doi.org/10.1371/journal.pone.0103325

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions